{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004750","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.399352+00:00","generated_at":"2026-06-20T17:46:55.070085+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroPace reports Q4 2022 preliminary revenue $12.8M (+16% YoY); appoints Dr. Uri Geiger to board","bullets":["Q4 2022 total revenue expected ~$12.8M, up 16% from $11.0M in Q4 2021; initial implant revenue $9.8M (+15%).","Full-year 2022 revenue expected ~$45.5M, flat vs $45.2M in 2021; initial implant revenue $35.7M (+6%).","Dr. Uri Geiger, founder of Accelmed Partners, appointed to Board effective Jan 5, 2023; granted option for 120,521 shares at $1.535.","Replacement implant revenue declined 44% in Q4 ($1.4M) and 29% for FY2022 ($8.2M); DIXI Medical contributed $1.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004750","json":"https://secwatch.observer/filing/0001193125-23-004750.json","markdown":"https://secwatch.observer/filing/0001193125-23-004750.md","text":"https://secwatch.observer/filing/0001193125-23-004750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/d407794d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:46:55.070085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84a9ec8e1b504e5230e45c59fdb028962bca5b77","claim":"NeuroPace Inc reported fiscal quarter and year ended December 31, 2022 results: revenue approximately $12.8 million.","evidence_excerpt":"December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors. Preliminary Unaudited Fourth Quarter 2022 • Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021. • Initial implant revenue is expected to be approximately $9.8 million, representing growth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter and year ended December 31, 2022"},{"label":"Revenue","value":"approximately $12.8 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"dd10f4f944","claim":"Dr. Uri Geiger was appointed as Director at NeuroPace Inc.","evidence_excerpt":"On January 4, 2023, the NeuroPace Board appointed Dr. Uri Geiger as a Class III director, effective as of January 5, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000119312523004750/0001193125-23-004750-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}